Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

Efficacy of the combination of trametinib and dabrafenib in isogenic cell lines with different KRAS mutational background In the entire panel of cell lines tested (Additional file 1 : Table S1), the association between KRAS mutational status and functional response to combination treatment did not reach statistical significance ( p value according to Mann-Whitney test 0.84; Additional file 1 : Figure S6); however, since the combination appeared to be synergistic in the majority of KRAS -mut cell lines and the occurrence of paradoxical ERK activation upon selective BRAF inhibition was originally described in KRAS -mut contexts [ 11 ], we investigated the effects of dabrafenib and trametinib, alone and in combination, in two KRAS isogenic tumor cell line models.

also in 111,027 other papers